---
title: "Eli Lilly hits record high in premarket"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305645505.md"
description: "Eli Lilly rose 1.03% to US$1458.30. Up 7.84% over five sessions and up 36.52% YTD."
datetime: "2026-11-16T09:26:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305645505.md)
  - [en](https://longbridge.com/en/news/305645505.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305645505.md)
generator: "portal-rs"
---

# Eli Lilly hits record high in premarket

Eli Lilly (LLY.US) rose more than **1%** in premarket trading to a record high of **$1,458.30**.

The stock is up 7.84% over the past five sessions and up 36.52% year to date. It sits 72.21% above its 52-week low of US$846.80.

The Nasdaq Composite is up 2.27% over the past five sessions and up 8.15% year to date.

At the ObesityWeek 2026 conference, the company reported that its phase 2 candidate EloraTZP achieved average weight loss of 23.3%, or about 54.1 pounds, in adults with overweight or obesity and type 2 diabetes, while significantly improving hemoglobin A1c levels. Phase 3 data showed retatrutide reduced the severity of obstructive sleep apnea and knee osteoarthritis pain, and Zepbound lowered BMI by 21.4% in adolescents.

Separately, China's National Medical Products Administration approved Eli Lilly's oral GLP-1 weight-loss drug orforglipron calcium tablets on Nov. 12 for long-term weight management in adults, marking the first oral GLP-1 therapy cleared in the country. The company has also broken ground on a $3.5 billion advanced manufacturing facility in Pennsylvania focused on next-generation injectable obesity treatments, with operations expected to begin in 2031.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)

## Related News & Research

- [Stipple Bio Enters Multi-Target Oncology Collaboration With Eli Lilly](https://longbridge.com/en/news/305722464.md)
- [Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion](https://longbridge.com/en/news/305722471.md)
- [Eli Lilly inks cancer pact worth up to $5.9bn with Stipple Bio](https://longbridge.com/en/news/305856885.md)
- [Lilly to buy Calytrix Bio for up to $1.5 billion](https://longbridge.com/en/news/305668502.md)
- [Eli Lilly’s EloraTZP delivers up to 23.3% average weight loss in Phase 2 trial](https://longbridge.com/en/news/305552298.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**